We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.


Vitalea Science Partners with SGS Life Science Services to Provide Microdosing Studies

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Vitalea Science Partners with SGS Life Science Services to Provide Microdosing Studies"

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Read time:

SGS announces that its Life Science Services division has selected Vitalea Science as a partner for providing Microdosing studies based on the Accelerator Mass Spectrometry (AMS) technology. This partnership further strengthens the complementary services offered by both SGS and Vitalea in executing early clinical trials based on the exploratory-IND concept.

Within the past three years, early phase clinical trials (Phase I-IIa) have evolved in process and purpose. New technology applications and shifts in the traditional drug development paradigm allow more information about drug candidates to be captured earlier in the process.

By harnessing the power of the AMS atom counter, one is able to collect ADME, bioavailability, and pharmacokinetic evaluations at the very earliest stages of clinical drug development: Phase 0 microdosing and Phase I microtracing. Streamlining early clinical development with microdosing and microtracers enables better development decisions, increasing potential success while reducing costs of failure for new drugs, formulations and delivery strategies.

In partnering with Vitalea Science, SGS is able to combine its own state of the art Phase I and bioanalytical facilities with Vitalea's AMS technology to provide clients with the necessary tools to execute these microdosing and microtracing studies. With new regulations in place as of June 2007, these exploratory IND studies can now be executed in SGS' Belgian facility.